You searched for: mutants (Engelska - Kroatiska)

well , it 's one or two mutants .
pa , jedan ili dva mutanata .

and our long-lived mutants are too .
i naši dugovječni mutanti također .

we kill bacteria with traditional antibiotics and that selects for resistant mutants .
ubijamo bakterije tradicionalnim antibioticima a to selekcionira otporne mutante .

it turns out that these long-lived mutants are more resistant to all these diseases .
ispada da su ovi dugovječni mutanti otporniji na sve ove bolesti .

m184v mutants display greatly reduced susceptibility to lamivudine and show diminished viral replicative capacity in vitro.
mutante m184v imaju znatno smanjenu osjetljivost na lamivudin i umanjeni kapacitet replikacije virusa in vitro.

these substitutions were correlated with varying levels of reduced enfuvirtide susceptibility in hiv site- directed mutants.
te su supstitucije bile u korelaciji s različitim razinama smanjene osjetljivosti na enfuvirtid u lokacijski usmjerenim mutantima hiv-a.

the k65r, m184v, and k65r+m184v mutants of hiv-1 remain fully susceptible to rilpivirine.
mutacije k65r, m184v i k65r+m184v virusa hiv-1 ostaju potpuno osjetljive na rilpivirin.

finally , we will test our predictions in the lab by growing e. coli mutants lacking a single gene in the presence of antibiotics .
na kraju ćemo testirati naša predviđanja u laboratoriju uzgajajući ( u prisustvu antibiotika ) mutante e . coli kojima nedostaje jedan gen .

as a consequence of this " reckless " dna degradation , populations of reca mutants contain a large proportion of anucleate cells .
uslijed ovakve " neobuzdane " razgradnje dna , u populacijama reca mutanata pojavljuje se značajan udio anukleiranih stanica .

additionally, resistance to simeprevir was evaluated in hcv genotype 1a and 1b replicon assays using site-directed mutants and chimeric replicons carrying ns3 sequences derived from clinical isolates.
dodatno, rezistencija na simeprevir bila je procijenjena u testovima replikona hcv-a genotipa 1a i 1b koristeći ciljane mutante i kimerne replikone koji su nosili ns3 sekvence derivirane iz kliničkih izolata.

g118r lowers the susceptibility to dolutegravir in site directed mutants (fc 10), but was not detected in patients receiving dolutegravir in the phase iii program.
mutacija g118r smanjuje osjetljivost izolata s ciljanom mutagenezom (engl. site directed mutants) na dolutegravir (fc 10), ali nije pronađena u bolesnika koji su primali dolutegravir u programu ispitivanja faze iii.

in serial passage with strain nl432, starting with site directed mutants harbouring n155h or e92q, no further selection of resistance was seen (fc unchanged around 1).
u serijskoj pasaži sa sojem nl432, koja je započela s izolatima s ciljanom mutagenezom i mutacijom n155h ili e92q, nije primijećena daljnja selekcija rezistencije (fc od približno 1 ostao je nepromijenjen).

continued passage in increasing concentrations of drug resulted in selection for double rt mutants 65r/184v and 74v/184v or triple rt mutant 74v/115y/184v.
daljnja pasaža uz povećanje koncentracija lijeka dovela je do izdvajanja dvostrukih mutanata rt-a 65r/184v i 74v/184v ili trostrukog mutanta rt-a 74v/115y/184v.

in contrast, starting with mutants harbouring mutation q148h (fc 1), a variety of secondary mutations were seen with a consequent increase of fc to values >10.
nasuprot tome, ako je pasaža započela s mutantima koji su imali mutaciju q148h (fc 1), primijećen je niz sekundarnih mutacija i posljedičan porast vrijednosti fc na >10.

0.51 (95% ci: 0.39, 0.67) for braf wild type and 0.74 (95% ci: 0.46, 1.18) for braf mutant with prior braf treatment.
0,51 (95% ci: 0,39; 0,67) za bolesnike s divljim tipom gena braf i 0,74 (95% ci: 0,46; 1,18) za bolesnike s mutacijom u genu braf koji su prethodno primali braf terapiju.